Key result
Inclisiran linked to ~55% reduction in LDL-C at 8 days following acute STEMI.
Why the study?
To evaluate the effect of intensive lipid-lowering therapy, including inclisiran prescribed in the acute phase of STEMI, on the lipid profile of patients at extremely high risk of cardiovascular complications.
Does inclisiran improve the lipid profile in patients with STEMI and an extremely high risk of cardiovascular complications during the acute phase?
Cohort (n=20)
No
Does inclisiran improve the lipid profile in patients with STEMI and an extremely high risk of cardiovascular complications during the acute phase?
Early administration of inclisiran during the acute in-hospital phase of STEMI safely and rapidly lowers LDL-C by over 55% within 8 days in patients at extremely high cardiovascular risk.
May enable early intensive LDL-C lowering in acute STEMI; leaves open effects on clinical outcomes.
Aim To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).Material and methods This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.Results Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p<0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p<0.001).Conclusion The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.
No takes yet. Share an insight, caveat, or question.
Хрипун et al. (2025) conducted a cohort in STEMI with extremely high risk of cardiovascular complications (n=20). Inclisiran was evaluated on Low-density lipoprotein cholesterol (LDL-C) level at 8±1 days (55.4% reduction, p=<0.001). Inclisiran significantly decreased low-density lipoprotein cholesterol by 55.4% (from 3.59 to 1.60 mmol/l, p<0.001) at 8 days when prescribed in the acute phase of STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: